Interview with Guillaume DRIANNO, General Manager, Servier Brasil
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Address: Estrada dos Bandeirantes, 4211
22775-113 – Rio de Janeiro – RJ,Brazil
Tel: (55 21) 2142-1414
Web: http://www.servier.com.br/
Servier Brasil is the first subsidiary of the Servier in Latin America, being present in the country for more than 35 years. In 2001 it opened an International Center of Therapeutic Research in Rio de Janeiro demonstrating a commitment to strengthening their presence in Brazil and Latin America.
Since the opening of its new modern factory in Jacarepaguá, Rio de Janeiro, Servier Brazil has been preparing to become a major supplier of Servier’s innovative drugs to the Brazilian and Latin American market.
Valdoxan, Procoralan 7,5mg, Coversyl, Coversyl Plus, Natrilix SR, Daflon 500, Diamicron MR, Protos, Vastarel, Arcalion , Trivastal Retard, Muphoran, Locabiotal .
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
See our Cookie Privacy Policy Here
